TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15477510

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11181283

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 27
Study: 9693578

Group type: EXPERIMENTAL
Intervention: Total occlusal reduction
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Simulated occlusal reduction (nonfunctional cusp reduction)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (occlusion untouched)
Number of subjects: 117
Study: 8169337

Group type: EXPERIMENTAL
Intervention: Captopril, 25 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3045351

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (gum) used ad lib for smoking urges or on a fixed schedule (12 pieces per day)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (gum) used on a fixed schedule (12 pieces per day)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo and no gum groups
Number of subjects: 600
Study: 31816096

Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 78

Group type: COMPARATOR
Intervention: Microscopic approach
Number of subjects: 78
Study: 29490102

Group type: EXPERIMENTAL
Intervention: Intensive behavior change intervention (BCI)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Nonintensive control group
Number of subjects: 457
Study: 28689785

Group type: EXPERIMENTAL
Intervention: Tranexamic acid administration
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 134
Study: 26329694

Group type: EXPERIMENTAL
Intervention: Massage and mental training (n=19)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Massage (n=19)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Mental training (n=19)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pause (n=19)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (n=17)
Number of subjects: 93
Study: 24276838

Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate (MgSO4) 100 mg/kg every 8 hours
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate (MgSO4)
Number of subjects: 104
Study: 21689707

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study: 18343748

Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g once daily for 3 days
Number of subjects: 267

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 875/125 mg twice daily for 7 days
Number of subjects: 267
Study: 16580659

Group type: EXPERIMENTAL
Intervention: cTnI measured on the DPC Immulite
Number of subjects: 213

Group type: COMPARATOR
Intervention: cTnT measured on Elecsys 1010
Number of subjects: 213
Study: 14712970

Group type: EXPERIMENTAL
Intervention: 125 mg ginger extract (EV.EXT35; equivalent to 1.5 g of dried ginger) given four times per day for 4 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 11095428

Group type: EXPERIMENTAL
Intervention: Short-term fasting (2.5-day)
Number of subjects: 8
Study: 9218089

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg 30 min before meals)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg 60 min before meals)
Number of subjects: 11
Study: 8475148

Group type: EXPERIMENTAL
Intervention: Large‐celled alternating pressure mattresses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small‐celled mattresses
Number of subjects: 0
Study: 3892679

Group type: EXPERIMENTAL
Intervention: 30mg omeprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60mg omeprazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no omeprazole)
Number of subjects: 12
Study: 30919005

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.057 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo haloperidol
Number of subjects: 28
Study: 29627268

Group type: EXPERIMENTAL
Intervention: Communication intervention using specific lexical formulations ('do you have 'any' vs. 'some' other concerns?')
Number of subjects: 0
Study: 26950204

Group type: EXPERIMENTAL
Intervention: Low dose of TA-65 (250 U)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: High dose of TA-65 (1000 U)
Number of subjects: 117
Study: 1449041

Group type: EXPERIMENTAL
Intervention: 100 micrograms of levothyroxine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 150 micrograms of iodide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 micrograms of iodide plus 50 micrograms of levothyroxine
Number of subjects: 30

Group type: COMPARATOR
Intervention: levothyroxine
Number of subjects: 30
Study: 22864277

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 6 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 6 months
Number of subjects: 40
Study: 20045151

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 6 months including health monitoring, counseling, health education, exercise, and dieting.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 6 months.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 52
Study: 18779236

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (home monitoring with a blood glucose meter)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Continuous glucose monitoring and Control group
Number of subjects: 322
Study: 15966877

Group type: EXPERIMENTAL
Intervention: BDX Coll + GTR
Number of subjects: 32

Group type: COMPARATOR
Intervention: Access flap surgery
Number of subjects: 32
Study: 12202120

Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid (20mg hyaluronic acid/2ml Hyalart) administered via five injections (one injection per week)
Number of subjects: 43
Study: 10353368

Group type: EXPERIMENTAL
Intervention: Dorsolateral prefrontal lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hippocampal lesions
Number of subjects: 0
Study: 7813259

Group type: EXPERIMENTAL
Intervention: PCP score (PCPSc) assessed on treatment days D0, D3, D7, D14, and D21
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: LDH levels during treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: PaO2 at hospital admission
Number of subjects: 78
Study: 2007104

Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine
Number of subjects: 20
Study: 6386634

Group type: EXPERIMENTAL
Intervention: Enzym-Paractol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30887607

Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 2000
Study: 30355364

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 134

Group type: COMPARATOR
Intervention: Prolonged exposure
Number of subjects: 134
Study: 25302581

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (futhan)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 73
Study: 22706414

Group type: EXPERIMENTAL
Intervention: Dimebon add-on treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 20050336

Group type: EXPERIMENTAL
Intervention: Vancomycin plus rifampicin (1 g intravenous every 12 hrs plus 300 mg twice daily by mouth)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Vancomycin only
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vancomycin plus rifampicin
Number of subjects: 93
Study: 17296974

Group type: EXPERIMENTAL
Intervention: Oblimersen (3 mg/kg/d as a 7-day continuous intravenous infusion) plus fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) for 3 days, for up to six cycles.
Number of subjects: 241

Group type: COMPARATOR
Intervention: Fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) for 3 days (chemotherapy-only group).
Number of subjects: 241
Study: 17950856

Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta every 2 weeks
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta every 4 weeks
Number of subjects: 447

Group type: COMPARATOR
Intervention: Epoetin treatment (control)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: All groups (methoxy polyethylene glycol-epoetin beta and epoetin)
Number of subjects: 447
Study: 15572737

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day) combined with ongoing lithium or valproate
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo combined with ongoing lithium or valproate
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Olanzapine co-therapy
Number of subjects: 85
Study: 11153292

Group type: EXPERIMENTAL
Intervention: Ketorolac 10.5 mg subcutaneously at the end of surgery followed by a subcutaneous infusion of 1.75 mg/h for 24 to 36 hours
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline (equivalent volume)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ketorolac and Saline
Number of subjects: 72
Study: 9185028

Group type: EXPERIMENTAL
Intervention: Haptoglobin phenotype allele 1
Number of subjects: 39

Group type: COMPARATOR
Intervention: Haptoglobin phenotype allele 2
Number of subjects: 39
Study: 1585039

Group type: EXPERIMENTAL
Intervention: Morning bowel training group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Scheduled suppository use
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bowel training group coinciding with previous pattern
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bowel training group conflicting with previous pattern
Number of subjects: 46
Study: 3895405

Group type: EXPERIMENTAL
Intervention: Trypure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Varidase
Number of subjects: 18
Study: 30782236

Group type: EXPERIMENTAL
Intervention: Integrated mental health and disaster preparedness intervention
Number of subjects: 480
Study: 30008080

Group type: EXPERIMENTAL
Intervention: Animated instructions on tablets
Number of subjects: 12841

Group type: EXPERIMENTAL
Intervention: Hands-on training
Number of subjects: 12841

Group type: EXPERIMENTAL
Intervention: Hands-on training in Hospital 1
Number of subjects: 12841

Group type: EXPERIMENTAL
Intervention: Hands-on training in Hospital 2
Number of subjects: 12841
Study: 27090301

Group type: EXPERIMENTAL
Intervention: Ketamine (single sub-anesthetic dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 25650044

Group type: EXPERIMENTAL
Intervention: High-volume CVVH (4000 mL/h)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-volume CVVH (2000 mL/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (abdominal infection)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups (before treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups (after treatment)
Number of subjects: 28
Study: 23971855

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy with ultrasonic dissection (MC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 88
Study: 22044553

Group type: EXPERIMENTAL
Intervention: Integrated home visit package delivered by community health workers, including two antenatal visits, a postnatal visit within 48 hours of birth, and four additional visits during the first two months of the infant's life.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 120
Study: 18852183

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering treatment (including angiotensin-converting enzyme inhibitors, calcium antagonists, angiotensin receptor blockers, diuretics/beta-blockers)
Number of subjects: 190617
Study: 16582060

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 327

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 327
Study: 14578545

Group type: EXPERIMENTAL
Intervention: HIV prevention interventions (specific details not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of HIV prevention interventions (specific details not provided)
Number of subjects: 0
Study: 10732745

Group type: EXPERIMENTAL
Intervention: Nine cycles of dose-escalated FEC (fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Three cycles of FEC followed by high-dose chemotherapy with alkylating agents (CTCb)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Six cycles of standard intravenous CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 36
Study: 9004446

Group type: EXPERIMENTAL
Intervention: Three dose pre-exposure series (days 0, 7, and 28) followed by one booster dose (day 360)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five dose simulated post-exposure series (days 0, 3, 7, 14, and 28)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lyssavac‐HDC vaccine
Number of subjects: 0
Study: 1547049

Group type: EXPERIMENTAL
Intervention: metoprolol 1 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: propranolol 1 mg
Number of subjects: 30
Study: 3890601

Group type: EXPERIMENTAL
Intervention: Fenoterol inhalation powder
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fenoterol MDI
Number of subjects: 20
Study: 31248471

Group type: EXPERIMENTAL
Intervention: GSP301 (olopatadine 665 μg and mometasone 25 μg)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo pH 3.7
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo 7.0
Number of subjects: 601
Study: 29235162

Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg, thrice daily for 12 weeks)
Number of subjects: 82
Study: 26928828

Group type: EXPERIMENTAL
Intervention: Free malaria rapid diagnostic test (RDT) offered to 37.6% of patients
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Patients feeling relatively healthy by the second day of treatment
Number of subjects: 1525
Study: 24488335

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 66
Study: 22682063

Group type: COMPARATOR
Intervention: Usual care (control) group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intervention group (strength training and walking program)
Number of subjects: 100
Study: 17437727

Group type: EXPERIMENTAL
Intervention: Baseline platelet count >= 234 x 10(9)/L
Number of subjects: 2021

Group type: COMPARATOR
Intervention: Baseline platelet count < 234 x 10(9)/L
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: Higher baseline platelet count
Number of subjects: 2021

Group type: COMPARATOR
Intervention: Lower baseline platelet count
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: Platelet count quartiles
Number of subjects: 2021
Study: 15126550

Group type: EXPERIMENTAL
Intervention: 1000 mg Testosterone Undecanoate (TU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1000 mg Testosterone Undecanoate (TU) plus 150 mg Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1000 mg Testosterone Undecanoate (TU) plus 300 mg Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (baseline period)
Number of subjects: 30
Study: 11377113

Group type: COMPARATOR
Intervention: Placebo-controlled RCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Augmented methodological stringency
Number of subjects: 0
Study: 9458602

Group type: EXPERIMENTAL
Intervention: Bass appliance treatment for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 47
Study: 7962682

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (7 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (14 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery night after active nicotine patch
Number of subjects: 12
Study: 3619425

Group type: EXPERIMENTAL
Intervention: Cefoperazone 1 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefoperazone 2 g
Number of subjects: 20
Study: 31742615

Group type: EXPERIMENTAL
Intervention: High-Dose Vitamin D Supplementation (10,000 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-Dose Vitamin D Supplementation (400 IU)
Number of subjects: 0
Study: 28960888

Group type: COMPARATOR
Intervention: Naldemedine (0.1-100 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Naldemedine (3-30 mg once daily for 10 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Naldemedine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 26537155

Group type: EXPERIMENTAL
Intervention: 6 mg nicotine gum
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 75 mg moclobemide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of 6 mg nicotine gum and 75 mg moclobemide
Number of subjects: 24
Study: 24243529

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dapagliflozin (Control)
Number of subjects: 0
Study: 22914208

Group type: EXPERIMENTAL
Intervention: 0.005% estriol vaginal gel (50 μg per application, 1 g daily for 3 weeks, then twice weekly up to 12 weeks)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: 0.005% estriol vaginal gel
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 167
Study: 19732072

Group type: EXPERIMENTAL
Intervention: Topiramate during the 6-month open-label phase
Number of subjects: 811

Group type: COMPARATOR
Intervention: Topiramate during the 6-month double-blind phase
Number of subjects: 811
Study: 17395395

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA) 2.5 mg for 1 month and 5 mg for 2 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA)
Number of subjects: 20
Study: 15761420

Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/wk
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Efalizumab 2 mg/kg/wk
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Efalizumab (1 or 2 mg/kg)
Number of subjects: 498
Study: 12084137

Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 131
Study: 10561135

Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (MAP) goal of 92 mm Hg or less (group I)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Mean arterial blood pressure (MAP) goal of 100 to 107 mm Hg (group II)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 129
Study: 8703598

Group type: EXPERIMENTAL
Intervention: Surgery with lingual flap retraction
Number of subjects: 771

Group type: COMPARATOR
Intervention: Surgery without lingual flap retraction
Number of subjects: 771
Study: 1924658

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 17
Study: 6287838

Group type: EXPERIMENTAL
Intervention: Wheat bran (20 g/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Corn bran (20 g/day)
Number of subjects: 10
Study: 30343489

Group type: EXPERIMENTAL
Intervention: Automated telephone‐based symptom and side effect monitoring with physician feedback over 6 months
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Usual care plus three non‐interactive diabetes educational calls
Number of subjects: 1270
Study: 28345425

Group type: EXPERIMENTAL
Intervention: 1% diclofenac/3% menthol gel (n=117)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: 1% diclofenac (n=112)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: 3% menthol (n=77)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo (n=75)
Number of subjects: 385
Study: 25391601

Group type: EXPERIMENTAL
Intervention: Interventionist-led (IL) group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Self-guided (SG) group
Number of subjects: 99
Study: 25117129

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 98792
Study: 22567095

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 19079812

Group type: EXPERIMENTAL
Intervention: Arterial switch operation with deep hypothermia and predominantly total circulatory arrest
Number of subjects: 155

Group type: COMPARATOR
Intervention: Arterial switch operation with predominantly low-flow continuous cardiopulmonary bypass
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Postoperative seizures
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Children with academic problems at age 8
Number of subjects: 155
Study: 17314119

Group type: COMPARATOR
Intervention: Risedronate (placebo group)
Number of subjects: 2546
Study: 15099140

Group type: EXPERIMENTAL
Intervention: Local confidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global confidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informing participants about normative status of estimates below 50%
Number of subjects: 0
Study: 10843263

Group type: EXPERIMENTAL
Intervention: Procedural verbalization
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Associative verbalization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 60
Study: 9324620

Group type: EXPERIMENTAL
Intervention: Intrafusin 10% (10 ml/kg BW/24 h of 10% amino acid solution)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aminosteril 10% (10 ml/kg BW/24 h of 10% amino acid solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic electrolyte solution (Jonosteril, control group) (10 ml/kg BW/24 h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intrafusin 10%
Number of subjects: 30
Study: 7968327

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (0.3 microgram/kg intravenous infusion one hour after cardiopulmonary bypass)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48